A phase Ib/II, multicenter, open label, study of LEE011 in combination with MEK162 in adult patients with NRAS mutant melanoma
A study for patients with mutant melanoma using study drugs LEE011 in combination with MEK162
Sponsor: Novartis Pharmaceuticals Corporation
Enrolling: Male and Female Patients
IRB Number: AAAN6610
U.S. Govt. ID: NCT01781572
Contact: Palak Thaker: 212-305-2055 / pt2433@cumc.columbia.edu
Additional Study Information: The purpose of this study is to find out if the drugs LEE011 and MEK162, administered in combination, are safe and effective in treating people who have melanoma. Specifically, this study will evaluate the effects of the combination of the two drugs, LEE011 and MEK162, in melanoma, carrying specific mutation in a gene called NRAS. The changes in the NRAS gene may lead to cancer growth.
This study is closed
Gary Schwartz, MD
Do You Qualify?
Do you have a confirmed diagnosis of locally advanced or metastic NRAS mutant melanoma? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Palak Thaker